ClinicalTrials.gg
RecruitingNCT07464132Updated Mar 11, 2026

Application of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases

A Phase 1/2 interventional study of Injection of 68Ga-NI-FAPI in Tumor, Cardiovascular Diseases and Pulmonary Fibrosis, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Peking Union Medical College Hospital · Phase 1/2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to conduct clinical research on [68Ga] Ga-NI-FAPI-04 PET/CT imaging and further investigate its diagnostic value in fibroblast activation related diseases.

02

Conditions studied

  • Tumor
  • Cardiovascular Diseases
  • Pulmonary Fibrosis
  • Rheumatic Immune Diseases Involving Large Blood Vessels
  • Hypertrophic Cardiomyopathy (HCM)
  • Other Hypoxic and Fibroblast Activated Diseases
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1: 18-85 years old

    2: Tumor patients can undergo surgery or to obtain pathological diagnosis

    3: Ability to understand and sign forms

    4: Expected survival period exceeding 6 months and able to receive follow-up

    5: Healthy volunteers without chronic medical history of hypertension, diabetes, coronary heart disease, kidney disease, tumor, etc

Exclusion criteria

Exclusion Criteria:

  • 1: Pregnant or lactating women

    2: Patients allergic to research drug ingredients

    3: Patients with severe liver and kidney dysfunction (blood creatinine levels exceeding 159 μ mol/L)

    4: Patients who participate in other clinical trials and interfere with the results of this study

    5: Patients with severe illness who cannot cooperate with the examination

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    NI-FAPI group

    Injection of \[68Ga\]Ga-NI-FAPI

    Drug: Injection of 68Ga-NI-FAPI

Interventions

  • DrugInjection of 68Ga-NI-FAPI

    Subjects were injected with 68Ga-NI-FAPI at 0.4-0.5mci/kg body weight

06

What researchers measure

Primary outcomes

  1. Analysis of PET/CT Images of [68Ga] Ga-NI-FAPI-04

    Semi quantitative analysis (measuring lesion standard uptake value (SUV), then calculating lesion SUV to liver/blood pool SUV ratio)

    Time frame: Within 30-120 minutes after intravenous injection of imaging agent

07

Study locations

1 of 1 sites recruiting
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
    Beijing, Beijing Municipality, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Feb 2027, 14 months after the start.

Of 102 non-industry phase 1/2 interventional studies under Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 111. This study's planned 14 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 11, 2026
StartActual
Dec 17, 2025
Primary completionEst.
Feb 17, 2027
CompletionEst.
Jun 17, 2027
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07464132
Responsible party
Zhaohui Zhu (Chief physician, Peking Union Medical College Hospital) — Principal investigator
First posted
Mar 11, 2026
Start date
Dec 17, 2025
Primary completion
Feb 17, 2027 (estimated)
Completion
Jun 17, 2027 (estimated)
Last update
Mar 11, 2026

Study contacts

Zhu
Contact
yfwyw1999@126.com
+86-13021115973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion